Investors seeking health care exposure often face a choice between specialized thematic strategies and broad sector funds. ARK Genomic Revolution ETF (ARKG) and Vanguard Health Care ETF (VHT) represent two distinct approaches within the same sector. ARKG pursues active, high-conviction bets on genomics innovation, while VHT delivers low-cost, rules-based access to the full spectrum of health care companies. These ETFs do not compete directly but offer alternative positioning for investors balancing growth potential against diversification and cost efficiency in the evolving health care landscape.
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) launched in 2014 that seeks long-term capital growth by investing primarily in equity securities of companies advancing the genomics revolution. The fund targets firms involved in gene therapy, bioinformatics, molecular medicine, and related technologies across health care, information technology, materials, energy, and consumer discretionary sectors. It typically holds 32 to 40 securities with significant concentration in the top positions. Recent top holdings include 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp (ABSI). The portfolio is heavily weighted toward health care, particularly biotechnology and life sciences tools. ARKG carries an expense ratio of 0.75% and employs an active, high-conviction rebalancing approach driven by fundamental research rather than an index.
Vanguard Health Care ETF (VHT) is a passively managed exchange-traded fund (ETF) launched in 2004 that seeks to track the performance of the MSCI US Investable Market Health Care 25/50 Index. The fund provides multicapitalization exposure to U.S. health care companies classified under the Global Industry Classification Standard (GICS). It employs full replication when possible and holds approximately 410 stocks. Top holdings typically include Eli Lilly and Co (LLY), Johnson & Johnson (JNJ), AbbVie Inc (ABBV), Merck & Co Inc (MRK), and UnitedHealth Group Inc (UNH). Sector allocations span pharmaceuticals, biotechnology, health care equipment, life sciences tools, and managed care. VHT maintains a low expense ratio of 0.09% and features quarterly rebalancing aligned with its underlying index methodology.
The health care sector continues to benefit from long-term structural drivers including aging populations, advances in precision medicine, and ongoing innovation in biotechnology and genomics. Regulatory developments around drug pricing and approval pathways, along with macroeconomic factors such as interest rate expectations, influence capital allocation between established pharmaceutical firms and higher-risk innovative companies. Genomics-focused themes face elevated volatility tied to clinical trial outcomes and technological breakthroughs, while broader health care exposure provides stability through diversified revenue streams. Capital flows into the sector remain supported by demographic trends and research and development pipelines, though policy uncertainty and valuation compression in growth segments present ongoing considerations for investors.
In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited greater sensitivity to shifts in investor sentiment toward high-growth biotechnology and genomics names, resulting in more pronounced movements during periods of sector rotation or interest rate changes. Its concentrated positioning amplifies the impact of individual company developments. Vanguard Health Care ETF (VHT), by contrast, has delivered more stable returns driven by the performance of large-cap pharmaceutical and managed care companies, with lower volatility attributable to its broad diversification across market capitalizations and subsectors. Relative positioning favors VHT for investors prioritizing cost efficiency and reduced drawdown risk, while ARKG suits those seeking differentiated exposure to emerging genomics technologies amid evolving innovation cycles.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore current opportunities across sectors including health care.
Based on structural characteristics, Tickeron’s AI would currently favor Vanguard Health Care ETF (VHT) due to its significantly lower expense ratio, broader diversification across approximately 410 holdings, and established liquidity profile. These factors support more consistent risk-adjusted exposure within the health care sector compared to the higher-cost, concentrated thematic approach of ARK Genomic Revolution ETF (ARKG). Investors seeking thematic upside may still consider ARKG for its specialized genomics focus, though the probabilistic assessment prioritizes VHT for most allocation objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARKG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
ARKG moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARKG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 249 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VHT declined for three days, in 243 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for VHT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VHT as a result. In 64 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for VHT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
VHT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 254 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
VHT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 200 of 251 cases where VHT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
| ARKG | VHT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Advances ODDS (%) | 13 days ago 90% | 11 days ago 81% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 80% |
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -5.64% | ||
| DNA - ARKG | 62% Loosely correlated | -9.02% | ||
| FATE - ARKG | 60% Loosely correlated | -9.01% | ||
| PHR - ARKG | 59% Loosely correlated | -3.88% | ||
| EDIT - ARKG | 59% Loosely correlated | -4.09% | ||
| BFLY - ARKG | 58% Loosely correlated | -7.69% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GSY | 50.13 | 0.03 | +0.06% |
| Invesco Ultra Short Duration ETF (GSY) | |||
| ACKY | 16.45 | -0.49 | -2.92% |
| VistaShares Target 15 ACKtivist Distribution ETF (ACKY) | |||
| CEE | 17.36 | -0.53 | -2.96% |
| Central and Eastern Europe Fund (The) | |||
| PLA | 23.06 | -0.79 | -3.33% |
| GraniteShares Autocallable PLTR ETF (PLA) | |||
| ATFV | 30.45 | -2.00 | -6.18% |
| Alger 35 ETF (ATFV) | |||